Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
Public ClinicalTrials.gov record NCT01434459. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Trial of Gemcitabine With TheraSphere® (Yttrium-90) in Patients With Hepatic Tumors of Pancreatobiliary Origin
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Therasphere is a form of treatment that has been designed to selectively deliver radiation to the cancer within the patient's liver. This form of treatment has been used in a number of clinical trials and has been approved for use in the treatment of liver cancer. The investigators want to test the safety of using Gemcitabine (a chemotherapy drug) with TheraSphere (radioactive beads that are injected directly into the blood vessel supplying the tumor in the liver) in patients with advanced pancreatobiliary tumors such as pancreatic cancer or cholangiocarcinoma (bile duct tumors) involving the liver.
Study identification
- NCT ID
- NCT01434459
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 9 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2011
- Primary completion
- Dec 31, 2013
- Completion
- Aug 31, 2014
- Last update posted
- May 3, 2015
2011 – 2014
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Emory University | Atlanta | Georgia | 30322 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Pancreatic Neoplasms trials
Other public records listing Pancreatic Neoplasms. Sorted by last update posted; newest first. Not a recommendation.
- NCT04137536: A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer Active, not recruiting
- NCT01950572: Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Recruiting
- NCT05914987: Determining Individualized Cancer Therapy in Pancreatic Cancer Recruiting
- NCT07542041: Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens Recruiting
- NCT05571839: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors Active, not recruiting
- NCT04406831: The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01434459, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2015 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01434459 live on ClinicalTrials.gov.